Title : A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.

Pub. Date : 2014 Aug

PMID : 24671507






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Treatment with vandetanib was associated with a reduction in soluble VEGFR-2 levels after two cycles but an increase in plasma VEGF levels. vandetanib vascular endothelial growth factor A Homo sapiens